Raltitrexed
SIGMA/R9156 - ≥98% (HPLC), solid
Synonym: L-Glutamic acid, N-
CAS Number: 112887-68-0
Empirical Formula (Hill Notation): C21H22N4O6S
Molecular Weight: 458.49
Linear Formula: C21H22N4O6S
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | off-white to light yellow |
| form | solid |
| originator | AstraZeneca |
| Quality Level | 100 ![]() |
| SMILES string | O=C1NC(C)=NC2=C1C=C(CN(C3 |
| solubility | DMSO: ≥40 mg/mL |
| H2O: ≥10 mg/mL | |
| storage temp. | 2-8°C |
| Biochem/physiol Actions: | Raltitrexed is a folate-based inhibitor of thymidylate synthase (TS) that is rapidly and extensively metabolized to its more potent polyglutamate derivatives. |
| Biochem/physiol Actions: | Raltitrexed is a folate-based inhibitor of thymidylate synthase (TS) that is rapidly and extensively metabolized to its more potent polyglutamate derivatives. By inhibiting the formation of precursor pyrimidine nucleotides, raltitrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cells. |
| Features and Benefits: | This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm . |
| Features and Benefits: | This compound was developed by AstraZeneca . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 10 mg in glass bottle |
| Packaging: | 50 mg in poly bottle |
| Symbol | ![]() GHS06,GHS08 |
| Signal word | Danger |
| Hazard statements | H300 - H360 |
| Precautionary statements | P201 - P301 + P310 + P330 |
| Hazard Codes | T |
| Risk Statements | 61-25 |
| Safety Statements | 53-45 |
| RIDADR | UN 2811 6.1 / PGIII |
| WGK Germany | WGK 2 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |



